Content by Sino Biological

As kinase dysfunction underlies many pathological conditions, scientists require high-quality active kinases for their therapeutic development programs.

Superior quality cytokines are crucial for reliable research results and the safe production of cancer cell therapies.

Sino Biological, Inc. (“Sino Biological” or the “Company”), is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.

Cutting edge technology delivers cytokines with high purity, high bioactivity, high batch-to-batch consistency, and high stability.

From early target discovery to preclinical development stages, researchers explore novel strategies for effective cell therapies in cancer treatment.

Optimizing organoid growth using pure, highly active, and consistent growth factors.

Sino Biological, Inc.(“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce a CRO services partnership with Ainnocence, Inc.  of San Jose, California.

A turnkey CRO service platform for recombinant protein and antibody expression and production

Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.

Sino Biological, Inc. (SHE: 301047) announced on Monday that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were issued for a total of 4.98 billion RMB raised during this initial public offering.

Sino Biological, Inc. today announced a co-development agreement with Nanommune Inc., an Irvine, California based biotechnology company specializing in the development and application of multiplex array technology.